Sprix nasal spray is a nonsteroidal anti-inflammatory drug designed for the short-term management of moderate to moderately-severe pain.
Financial terms of the two-year deal were not disclosed.
“Given the need for additional non-narcotic analgesics in the dental space, we believe Sprix nasal spray offers an attractive product profile that can complement the OraPharma line of oral health products,” chief operating officer Mark Strobeck said in prepared remarks. “This partnership, which expands our commercial reach, represents one aspect of our business development strategy which also includes acquisition of late-stage or approved assets and out-licensing of our Guardian Technology pipeline product candidates.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.